105 related articles for article (PubMed ID: 20547104)
1. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
Teicher BA
Curr Opin Pharmacol; 2010 Aug; 10(4):397-404. PubMed ID: 20547104
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
3. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
4. Effect of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose) polymerase, on cultured tumor cells.
Weltin D; Marchal J; Dufour P; Potworowski E; Oth D; Bischoff P
Oncol Res; 1994; 6(9):399-403. PubMed ID: 7703525
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Kim JC; Shin ES; Kim CW; Roh SA; Cho DH; Na YS; Kim TW; Kim MB; Hyun YL; Ro S; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3027-34. PubMed ID: 19661311
[TBL] [Abstract][Full Text] [Related]
6. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
8. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
10. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo.
Arandjelovic SS; Bjelogrlic KS; Malesevic NN; Tesic LjZ; Radulovic SS
J BUON; 2009; 14(2):271-9. PubMed ID: 19650178
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W; Bishton M; Johnstone RW; Prince HM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
[TBL] [Abstract][Full Text] [Related]
16. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Powell C; Mikropoulos C; Kaye SB; Nutting CM; Bhide SA; Newbold K; Harrington KJ
Cancer Treat Rev; 2010 Nov; 36(7):566-75. PubMed ID: 20409643
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
Wadler S; Schwartz EL
Cancer Res; 1990 Jun; 50(12):3473-86. PubMed ID: 1692761
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Thomas S; Munster PN
Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
